The Added Value of Genome-Wide Copy Numbers to Objectively Resolve Clonality of Multiple Tumors With Pulmonary Involvement and Ambiguous or Inconclusive Mutational Diagnosis [0.03%]
全基因组拷贝数在多原发肿瘤脉络不清或突变诊断不确切情况下的系谱解析中的应用价值评估
Jurriaan Janssen,Bárbara Andrade Barbosa,Tim R Mocking et al.
Jurriaan Janssen et al.
Introduction: The incidence of patients presenting with multiple cancers (MCs) and pulmonary involvement is increasing. Although next-generation sequencing mutation panels can discern metastases (clonal) from separate pri...
Rapid-onset Severe Cytokine Release Syndrome With Marked Interleukin-6 Increase and Acute Liver Injury After the First Tarlatamab Dose in SCLC: Case Report [0.03%]
塞瑞拉单抗首次给药后出现快速发作的重度细胞因子释放综合征、 interleukin-6 显著升高和急性肝损伤的 small cell lung cancer 患者病例报告
Kento Takagi,Go Saito,Toshiaki Inazaki et al.
Kento Takagi et al.
Tarlatamab is a novel bispecific T-cell engager therapy with promising efficacy in patients with previously treated extensive-stage SCLC. Cytokine release syndrome (CRS) is the most common adverse event related to tarlatamab, although sever...
Epidemiologic and Survival Analyses of Lung Cancer in Nagano Prefecture: Impact of Serial Low-Dose Computed Tomography Screening [0.03%]
长野县肺癌的流行病学和生存分析：连续低剂量计算机断层摄影筛查的影响
Tomonobu Koizumi,Kengo Otsuki,Yuichiro Maruyama
Tomonobu Koizumi
Introduction: Low-dose computed tomography (LDCT) screening for lung cancer has been implemented in many municipalities in Nagano prefecture. We analyzed epidemiologic and survival data of patients with lung cancer among ...
Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLC [0.03%]
不可切除III期非小细胞肺癌序贯化疗联合免疫治疗后同步放化疗的疗效及安全性：一项单臂、多中心2期试验
Arthi Sridhar,Aditi Singh,Scott Hansen et al.
Arthi Sridhar et al.
Background: The eighth edition of the International Association for the Study of Lung Cancer staging project reports a 5-year overall survival (OS) for stage IIIA, B, and C NSCLC of 41%, 24%, and 12%, respectively, highli...
Genetic Characteristics of Disease Flare After Lenvatinib Discontinuation in Patients With Thymic Carcinoma: A Brief Report [0.03%]
仑伐替尼停药后胸腺癌患者疾病加重的遗传特征简报
Tomoaki Nakamura,Tatsuya Yoshida,Ken Masuda et al.
Tomoaki Nakamura et al.
Introduction: Lenvatinib, an orally administered multitargeted kinase inhibitor, has exhibited antitumor activity against several cancer types, including thymic carcinomas. Although "disease flare" (a rapid worsening of t...
Machine Learning Models Using General and Tissue-Specific Feature Extractors for Accurate Subtyping of Biopsy Samples: Advancing Lung Cancer Diagnosis in Latin America [0.03%]
基于通用和组织特异性特征提取器的机器学习模型在活检样本精确诊断中的应用：推进拉丁美洲肺癌诊断技术的发展
Viviane Teixeira Loiola de Alencar,Felipe Navarro Balbino Alves,Guilherme de Souza Velozo et al.
Viviane Teixeira Loiola de Alencar et al.
Introduction: Lung cancer is the leading cause of cancer-related deaths worldwide, with accurate histologic subtype classification critical for diagnosis and treatment planning. Diagnostic variability and resource dispari...
Risk Factors Associated With Incidence of Lung Cancer in Never-Smokers: A Systematic Review and Meta-Analysis [0.03%]
一项无吸烟史的肺癌患者相关发病因素的系统回顾及荟萃分析
Sindhu Bhaarrati Naidu,Allegra Wisking,Akul Karoshi et al.
Sindhu Bhaarrati Naidu et al.
Objectives: Lung cancer is the leading cause of cancer mortality globally. Although often associated with smoking, up to 25% of cases worldwide and 50% in East Asia occur in "never-smokers." There are currently no robust ...
RELAY+: Final Overall Survival With Ramucirumab Plus Gefitinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC [0.03%]
RELAY+：雷莫芦单抗联合吉非替尼治疗EGFR突变的未经治疗的转移性NSCLC患者的总生存期最终分析结果
Makoto Nishio,Takashi Seto,Martin Reck et al.
Makoto Nishio et al.
Introduction: Ramucirumab (RAM) plus gefitinib (GEF) exhibited favorable efficacy and safety as first-line treatment in the primary analysis of the RELAY+ study of East Asian patients with metastatic EGFR-mutated NSCLC. W...
Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial [0.03%]
克唑替尼治疗有或无脑转移的ROS1阳性NSCLC患者：Ⅱ期METROS试验的事后分析
Lorenza Landi,Rita Chiari,Marcello Tiseo et al.
Lorenza Landi et al.
Introduction: Crizotinib, the first approved targeted therapy for ALK-positive advanced NSCLC, is also indicated for ROS1-rearranged NSCLC. This post hoc analysis of the phase II METROS trial explores long-term survival o...
Evaluating Circulating Tumor DNA Clearance as an Early Intermediate End Point Predicting Clinical Benefit in Metastatic Nonsquamous NSCLC After First-Line Chemoimmunotherapy [0.03%]
评估循环肿瘤DNA清除作为一线化疗免疫治疗后转移性非鳞状NSCLC临床获益的早期中间终点
Min Yuan,Haolun Ding,Weiwei Zhuang et al.
Min Yuan et al.
Introduction: In the first-line (1L) NSCLC setting, overall survival (OS) as a trial end point is increasingly challenging due to longer survival and confounding from novel later-line therapies. This study aims to evaluat...